Compugen Ltd. - הכנסה לפני ניכוי ריבית, מסים ופחת CGEN

The stability of Compugen Ltd. (CGEN) depends on partner payments and early test outcomes, which creates a financial deficit. EBITDA helps assess the issuer's real strength, where 0.00 serves as the current value of the parameter. Business growth is fueled by the AI platform and the alliance with Gilead, although protein synthesis relies entirely on external contractors.
Compugen - פילוחים אנליטיים ומדדי מפתח (CGEN)

Compugen Ltd. is scaling its immuno-oncology developments by leveraging advanced computing platforms to create innovative drugs. An analysis of daily cash inflows from core operations on GURU.Markets allows for a real-time assessment of the liquidity behind this growth, while cash-equivalent operating profit helps investors promptly detect flow stagnation or the risk of overpaying for the asset.